FDA pharmacologic class
GLP-1 receptor agonists
6 medicines are in FDA's class of GLP-1 receptor agonists (GLP-1 receptor agonists): tirzepatide (Zepbound), semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), orforglipron (Foundayo) and exenatide (Byetta); 2 combination products also contain one. 2 of the 8 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is foundayo 0.8 mg tablet at $20.89 per tablet (NADAC).
Which medicines are glp-1 receptor agonists?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Tirzepatide | Mounjaro, Zepbound | none listed | $538.68 per mL 10 mg/0.5 mL pen | Yes | No current entry | 0 |
| Semaglutide | Wegovy, Ozempic, Rybelsus | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued | 4 |
| Liraglutide | Victoza, Saxenda | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | Yes | In shortage | 3 |
| Dulaglutide | Trulicity | none listed | $487.57 per mL 0.75 mg/0.5 mL pen | Yes | No current entry | 2 |
| Orforglipron | Foundayo | none listed | $20.89 per tablet 0.8 mg tablet | Yes | No current entry | 0 |
| Exenatide | Byetta | 1 labeler | $300.17 per mL 10 mcg dose pen injection | No | No current entry | 1 |
| Insulin degludec and liraglutide | Xultophy | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | Yes | No current entry | 1 |
| Insulin glargine and lixisenatide | Soliqua | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price